- Home
- CBRL vs IMCR Comparison
CBRL vs IMCR Comparison
Compare CBRL & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- IMCR
- Stock Information
- Founded
- CBRL 1969
- IMCR 2008
- Country
- CBRL United States
- IMCR United Kingdom
- Employees
- CBRL N/A
- IMCR N/A
- Industry
- CBRL Restaurants
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBRL Consumer Discretionary
- IMCR Health Care
- Exchange
- CBRL Nasdaq
- IMCR Nasdaq
- Market Cap
- CBRL 1.3B
- IMCR 1.5B
- IPO Year
- CBRL N/A
- IMCR 2021
- Fundamental
- Price
- CBRL $61.08
- IMCR $31.15
- Analyst Decision
- CBRL Hold
- IMCR Buy
- Analyst Count
- CBRL 8
- IMCR 10
- Target Price
- CBRL $53.86
- IMCR $58.13
- AVG Volume (30 Days)
- CBRL 1.3M
- IMCR 473.9K
- Earning Date
- CBRL 06-05-2025
- IMCR 08-07-2025
- Dividend Yield
- CBRL 1.65%
- IMCR N/A
- EPS Growth
- CBRL N/A
- IMCR N/A
- EPS
- CBRL 2.58
- IMCR N/A
- Revenue
- CBRL $3,510,062,000.00
- IMCR $333,581,000.00
- Revenue This Year
- CBRL $1.97
- IMCR $26.82
- Revenue Next Year
- CBRL $1.61
- IMCR $8.15
- P/E Ratio
- CBRL $23.46
- IMCR N/A
- Revenue Growth
- CBRL 2.84
- IMCR 25.75
- 52 Week Low
- CBRL $33.86
- IMCR $23.15
- 52 Week High
- CBRL $65.43
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- CBRL 58.45
- IMCR 44.46
- Support Level
- CBRL $59.74
- IMCR $30.83
- Resistance Level
- CBRL $63.71
- IMCR $37.56
- Average True Range (ATR)
- CBRL 3.16
- IMCR 1.58
- MACD
- CBRL 0.09
- IMCR -0.59
- Stochastic Oscillator
- CBRL 77.64
- IMCR 15.64
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.